Colgate-Palmolive (NYSE:CL – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $105.11.
A number of research firms have commented on CL. StockNews.com upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a research note on Monday. TD Cowen dropped their price target on shares of Colgate-Palmolive from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. Wells Fargo & Company dropped their price target on shares of Colgate-Palmolive from $100.00 to $92.00 and set an “underweight” rating on the stock in a research note on Monday, October 28th. UBS Group boosted their price target on shares of Colgate-Palmolive from $119.00 to $122.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Finally, Sanford C. Bernstein boosted their price target on shares of Colgate-Palmolive from $100.00 to $103.00 and gave the stock a “market perform” rating in a research note on Tuesday, July 30th.
Colgate-Palmolive Trading Up 0.4 %
Colgate-Palmolive Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, November 15th. Shareholders of record on Friday, October 18th were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.10%. The ex-dividend date was Friday, October 18th. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 57.31%.
Insider Buying and Selling at Colgate-Palmolive
In other Colgate-Palmolive news, CFO Stanley J. Sutula III sold 45,410 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $94.11, for a total value of $4,273,535.10. Following the sale, the chief financial officer now owns 36,726 shares of the company’s stock, valued at $3,456,283.86. This represents a 55.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.37% of the company’s stock.
Hedge Funds Weigh In On Colgate-Palmolive
Institutional investors and hedge funds have recently modified their holdings of the company. E Fund Management Hong Kong Co. Ltd. purchased a new position in shares of Colgate-Palmolive during the second quarter valued at approximately $25,000. Continuum Advisory LLC lifted its stake in shares of Colgate-Palmolive by 46.5% during the second quarter. Continuum Advisory LLC now owns 394 shares of the company’s stock valued at $38,000 after buying an additional 125 shares during the period. Reston Wealth Management LLC purchased a new position in shares of Colgate-Palmolive during the third quarter valued at approximately $42,000. Capital Performance Advisors LLP purchased a new position in shares of Colgate-Palmolive during the third quarter valued at approximately $53,000. Finally, Prospera Private Wealth LLC purchased a new position in shares of Colgate-Palmolive during the third quarter valued at approximately $64,000. Hedge funds and other institutional investors own 80.41% of the company’s stock.
About Colgate-Palmolive
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
Further Reading
- Five stocks we like better than Colgate-Palmolive
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- How to invest in marijuana stocks in 7 steps
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- Stock Splits, Do They Really Impact Investors?
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.